Adjuvant Therapy for Colon Cancer: Genes, Genes… and the Patient in the Center
- PMID: 29678903
- DOI: 10.1158/1078-0432.CCR-18-0818
Adjuvant Therapy for Colon Cancer: Genes, Genes… and the Patient in the Center
Abstract
Although molecular subtype-based stratification and genomic signatures of increasing complexity are becoming a new strategy to guide therapeutic decisions in stage II/III colon cancer, several prognostic factors that can be easily obtained from formalin-fixed paraffin-embedded (FFPE) specimens should be considered to create combined models that better define individual patients' needs. Clin Cancer Res; 24(16); 3787-9. ©2018 AACRSee related article by Kandimalla et al., p. 3867.
©2018 American Association for Cancer Research.
Comment on
-
Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.Clin Cancer Res. 2018 Aug 15;24(16):3867-3877. doi: 10.1158/1078-0432.CCR-17-3236. Epub 2018 Mar 7. Clin Cancer Res. 2018. PMID: 29514841 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
